GHRP-6 vs Hexarelin
Potency versus appetite. Hexarelin is among the strongest GH-releasing peptides ever put into people; GHRP-6 is the milder relative whose hallmark is hunger. Neither is selective.
Short answer
GHRP-6 and hexarelin are both marketed for muscle and recovery and both have human clinical data, so the difference is in how they work and what their trials found. The headline human result for GHRP-6 is GH 15.4 ng/mL vs 5.5 on placebo after four overnight IV doses in normal men; no body-composition outcome data.
GHRP-6
Pulses GH short-term, but its most reliable real-world effect is a surge in appetite; no long-term human outcomes and not approved.
Full GHRP-6 evidence reviewHexarelin
One of the most potent GH secretagogues studied — but it also raises cortisol and prolactin, desensitizes with repeated use, and is unapproved.
Full Hexarelin evidence reviewGHRP-6 vs Hexarelin: head to head
- FDA status / approved use
GHRP-6
Not FDA-approved; sold as a gray-market research peptideHexarelin
Not an approved drug; sold as unregulated research material; prohibited by WADA- Marketed for
GHRP-6
Muscle, recovery, 'anti-aging'Hexarelin
Muscle, recovery, 'anti-aging'- Outcome areas
GHRP-6
Muscle / strength / lean mass; Injury recovery / tissue repair; Longevity / lifespanHexarelin
Muscle / strength / lean mass; Injury recovery / tissue repair; Longevity / lifespan- Evidence grade
GHRP-6
Clinical dataHexarelin
Clinical data- How it works
GHRP-6
Mimics ghrelin at its receptor, triggering a pulse of pituitary growth hormoneHexarelin
Acts at the ghrelin receptor to trigger pituitary GH release; also binds CD36- Route and dosing
GHRP-6
Injection, usually subcutaneous; also studied intravenous and oralHexarelin
Subcutaneous injection- Headline human result
GHRP-6
GH 15.4 ng/mL vs 5.5 on placebo after four overnight IV doses in normal men; no body-composition outcome dataHexarelin
Peak GH 68.4 µg/L vs 26.7 µg/L for GHRH after a 1 µg/kg IV dose in seven young men- Strongest evidence
GHRP-6
Jaffe, JCEM 1993GHRP-6 evidence reviewPubMed 7903313Hexarelin
Maccario, Eur J Endocrinol 2002Hexarelin evidence reviewPubMed 11888836- Key safety signal
GHRP-6
Strong appetite increase; raises ACTH and cortisol; GH response blunts with repeated dosingHexarelin
Raises cortisol and prolactin; GH response fades with continued dosing- How it is obtained
GHRP-6
Sold gray-market as a research chemical; no approved or legitimately compounded human productHexarelin
Sold gray-market as a research chemical; no approved or legitimately compounded human product
| GHRP-6 | Hexarelin | |
|---|---|---|
| FDA status / approved use | Not FDA-approved; sold as a gray-market research peptide | Not an approved drug; sold as unregulated research material; prohibited by WADA |
| Marketed for | Muscle, recovery, 'anti-aging' | Muscle, recovery, 'anti-aging' |
| Outcome areas | Muscle / strength / lean mass; Injury recovery / tissue repair; Longevity / lifespan | Muscle / strength / lean mass; Injury recovery / tissue repair; Longevity / lifespan |
| Evidence grade | Clinical data | Clinical data |
| How it works | Mimics ghrelin at its receptor, triggering a pulse of pituitary growth hormone | Acts at the ghrelin receptor to trigger pituitary GH release; also binds CD36 |
| Route and dosing | Injection, usually subcutaneous; also studied intravenous and oral | Subcutaneous injection |
| Headline human result | GH 15.4 ng/mL vs 5.5 on placebo after four overnight IV doses in normal men; no body-composition outcome data | Peak GH 68.4 µg/L vs 26.7 µg/L for GHRH after a 1 µg/kg IV dose in seven young men |
| Strongest evidence | Jaffe, JCEM 1993GHRP-6 evidence reviewPubMed 7903313 | Maccario, Eur J Endocrinol 2002Hexarelin evidence reviewPubMed 11888836 |
| Key safety signal | Strong appetite increase; raises ACTH and cortisol; GH response blunts with repeated dosing | Raises cortisol and prolactin; GH response fades with continued dosing |
| How it is obtained | Sold gray-market as a research chemical; no approved or legitimately compounded human product | Sold gray-market as a research chemical; no approved or legitimately compounded human product |
marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
- Clinical data:
- Tested in humans — but investigational, discontinued, or proven only on a surrogate marker (not the marketed outcome).
Our verdict
Hexarelin has the stronger measured GH effect, releasing substantially more GH than GHRH in controlled human comparisons, but it is not selective; repeated daily subcutaneous dosing raised prolactin, ACTH and cortisol alongside GH, and the GH response shows tachyphylaxis, attenuating with continued use. GHRP-6 also raises ACTH and cortisol, blunts with sustained dosing, and its most consistent real-world effect is appetite. Neither is an approved drug, both are sold as research material of unverified dose and purity, and both are prohibited in sport. Neither has human outcome trials for muscle, fat loss or aging, and they have not been compared directly.
GHRP-6 fits if
GHRP-6 is the relevant molecule for understanding ghrelin-driven hunger and the older multi-route GH-stimulation literature.
Hexarelin fits if
Hexarelin is worth reading about for its CD36 cardiovascular biology, which runs independent of growth hormone, but that work is preclinical and does not make it a therapy.
GHRP-6 vs Hexarelin: common questions
- Is either GHRP-6 or hexarelin FDA-approved?
- No. GHRP-6 is not FDA-approved; sold as a gray-market research peptide. Hexarelin is not an approved drug; sold as unregulated research material; prohibited by WADA.
- Which has stronger human evidence, GHRP-6 or hexarelin?
- Neither clearly. Both have human clinical data. The key source for GHRP-6 is Jaffe, JCEM 1993; for hexarelin, it is Maccario, Eur J Endocrinol 2002.
- What are the main safety concerns with GHRP-6 and hexarelin?
- For GHRP-6, watch for strong appetite increase; raises ACTH and cortisol; GH response blunts with repeated dosing. Hexarelin raises cortisol and prolactin; GH response fades with continued dosing.
Key studies behind each
GHRP-6
- Frieboes RM, Murck H, Maier P, et al. (1995). Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man. Neuroendocrinology. PubMed 7617137
- Jaffe CA, Ho PJ, Demott-Friberg R, et al. (1993). Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men. J Clin Endocrinol Metab. PubMed 7903313
- Frieboes RM, Murck H, Antonijevic IA, et al. (1999). Effects of growth hormone-releasing peptide-6 on the nocturnal secretion of GH, ACTH and cortisol and on the sleep EEG in man: role of routes of administration. J Neuroendocrinol. PubMed 10336729
- Bellone J, Ghizzoni L, Aimaretti G, et al. (1995). Growth hormone-releasing effect of oral growth hormone-releasing peptide 6 (GHRP-6) administration in children with short stature. Eur J Endocrinol. PubMed 7581965
Hexarelin
- Arvat E, Maccario M, Di Vito L, Broglio F, et al. (2001). Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. J Clin Endocrinol Metab. PubMed 11238504
- Maccario M, Veldhuis JD, Broglio F, Di Vito L, et al. (2002). Impact of two or three daily subcutaneous injections of hexarelin, a synthetic growth hormone (GH) secretagogue, on 24-h GH, prolactin, adrenocorticotropin and cortisol secretion in humans. Eur J Endocrinol. PubMed 11888836
- Raun K, Hansen BS, Johansen NL, Thøgersen H, et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. PubMed 9849822
- Rahim A, O'Neill PA, Shalet SM. (1998). Growth hormone status during long-term hexarelin therapy. J Clin Endocrinol Metab. PubMed 9589671
The full evidence reviews
- GHRP-6: the 'hunger' growth-hormone secretagogue, and what the evidence shows
GHRP-6 is a first-generation ghrelin-receptor agonist that pulses growth hormone — but its most reliable real-world effect is a strong, dose-dependent surge in appetite. Real short-term GH pharmacology, preclinical cytoprotection, no long-term human outcomes, and not FDA-approved.
Updated August 2026
- Hexarelin: a potent GH peptide — with cortisol, prolactin and desensitization in the fine print
Hexarelin is one of the most potent GH secretagogues studied — that part is real. But unlike the selective ipamorelin it also raises cortisol and prolactin, its GH effect fades with repeated use, and it’s unapproved, gray-market, WADA-banned material. A straight read.
Updated August 2026
Where to get it
Where to get peptide therapy
Clinician-led telehealth services that prescribe compounded peptides. The specific peptides offered vary by provider — confirm GHRP-6 availability before ordering.
Disclosure: Aminoscope is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. Partners are listed first; a commission never changes what we write about a provider. How we make money.
- Oak LongevityPartner
Low-cost sermorelin within a broader longevity stack
- HealthRXPartner
Compounded sermorelin within a broad longevity and weight-care menu
Bodybuilding Health+PartnerSermorelin from Bodybuilding.com's telehealth program
Provider reviews we publish: Solaya MDVevaRXIdgie HealthRX BellaEviora MDNew Wave Health